For a long time, children with the ultrarare genetic disease progeria, which causes rapid aging, didn’t have an FDA-approved therapy. But that’s about to change.
Friday, the FDA approved Zokinvy, or lonafarnib, to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies in patients ages 1 and above.
Zokinvy isn’t a cure. The drug, a farnesyltransferase inhibitor, targets the toxic buildup of progerin or progerin-like farnesylated proteins.
you may think that this found is not very important due to the rare of the disease but if this drug works to prevent rapid aging in children it may prevent rapid aging for all. which was always humans dream: youngness elixir!